Ambrx Biopharma, Inc.
AMAMDelisted Mar 7, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001990550
Ambrx Biopharma, Inc. was delisted on Mar 7, 2024; its insiders filed their last Form 4 on Mar 7, 2024; 68 institutions reported holding it in 13F filings for Q4 2023, worth $912.7M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 68
- Q4 2023, +25 vs. previous quarter
- 13F value
- $912.7M
- Reported value at the end of Q4 2023
- Superinvestors holding
- 0
- At the end of Q4 2023
Superinvestors holding AMAM, Q4 2023
No superinvestor reported holding AMAM at the end of Q4 2023.
Latest insider trades
Open-market purchases and sales by Ambrx Biopharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 31, 2023 (view filing) | Oct 27 | 4 days | Nelson SonjaChief Financial Officer | SSale | −12.8K | $9.82 | −$125.5K | −8.9%130.1K after | 10b5-1 |
| Oct 31, 2023 (view filing) | Oct 27 | 4 days | O'Connor Daniel J.President and CEO | SSale | −50.0K | $9.82 | −$491.1K | −12.7%342.8K after | 10b5-1 |
| Oct 25, 2023 (view filing)4:15 PM ET | Oct 23 | 2 days | Cormorant Asset Management, LP and 3 others10% Owner | PPurchase | +1.31M | $6.99 | +$9.14M | +13.2%11.2M after | |
| Sep 19, 2023 (view filing)4:49 PM ET | Sep 15-18 | 4 days | Cormorant Asset Management, LP and 3 others10% Owner | PPurchase | +2.15M | $9.12 | +$19.6M | +3.2%69.5M after | 2 lots |
| Jun 28, 2023 (view filing)4:45 PM ET | Jun 27 | 1 day | Darwin Global Master Fund, Ltd. and 2 others10% Owner | PPurchase | +37.7M | $1.99 | +$75.0M | –16.7M after | Derivative |
| Apr 20, 2023 (view filing)6:04 PM ET | Apr 18-20 | 2 days | Cormorant Asset Management, LP and 3 others10% Owner | PPurchase | +5.22M | $11.30 | +$59.0M | +8.4%67.3M after | 3 lots |
| Apr 17, 2023 (view filing)5:46 PM ET | Apr 13-17 | 4 days | Cormorant Asset Management, LP and 3 others10% Owner | PPurchase | +2.60M | $9.75 | +$25.3M | +4.4%62.1M after | 3 lots |
| Mar 16, 2023 (view filing)6:04 PM ET | Mar 14-16 | 2 days | Cormorant Asset Management, LP and 3 others10% Owner | PPurchase | +1.00M | $10.21 | +$10.2M | +1.9%53.5M after | 3 lots |
| Mar 8, 2023 (view filing) | Feb 27-Mar 6 | 9 daysLate | Darwin Global Management, Ltd.10% Owner | PPurchase | +26.0M | $0.9253 | +$24.1M | –11.3M after | Derivative3 lots |
Top 10 13F holders, Q4 2023
The largest institutional positions in Ambrx Biopharma, Inc. at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Darwin Global Management, Ltd. | 16,688,636 | $237.6M | 46.64% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 11,231,000 | $159.9M | 7.66% | +1,307,311+13.2% | Added |
| Paradigm Biocapital Advisors LP | 4,352,689 | $62.0M | 2.90% | +864,093+24.8% | Added |
| D. E. Shaw & Co., Inc. | 4,240,486 | $60.4M | 0.09% | +235,973+5.9% | Added |
| Deep Track Capital, LP | 3,710,412 | $52.8M | 1.85% | +3,710,412 | New |
| Nextech Invest AG | 3,129,300 | $44.6M | 8.30% | +3,129,300 | New |
| Balyasny Asset Management LLC | 2,154,700 | $30.7M | 0.09% | +2,154,700 | New |
| Logos Global Management LP | 2,100,000 | $29.9M | 3.33% | +1,985,000+1,726.1% | Added |
| VR Adviser, LLC | 2,070,000 | $29.5M | 2.02% | 00.0% | Unchanged |
| Citadel Advisors LLC | 2,042,212 | $29.1M | 0.03% | +1,273,387+165.6% | Added |